LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

New data on clinical decisions in NSCLC patients with uncommon EGFR mutations

Photo from wikipedia

ABSTRACT Introduction: Non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor (EGFR) mutations together account for approximately 10% of all EGFR mutations. The most common of which being… Click to show full abstract

ABSTRACT Introduction: Non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor (EGFR) mutations together account for approximately 10% of all EGFR mutations. The most common of which being G719X, S768I, L861Q, and exon 20 insertions. The clinical significance, particularly their response to EGFR tyrosine kinase inhibitors (TKIs) is largely unclear. Previous data is limited to a small fraction of patients in prospective studies and retrospective series. Recently, a combined analysis of patients with uncommon EGFR mutations in the Lux-Lung 2, Lux-Lung 3, Lux-Lung 6 trials provide new perspectives of uncommon EGFR mutations. Areas covered: This review reports the existing evidence from major prospective and retrospective studies, along with new data that focus on the clinical significance of uncommon EGFR mutations. Expert commentary: The clinical data of uncommon EGFR mutations should be interpreted carefully as data from prospective and retrospective studies are not considered at the same level of evidence.

Keywords: egfr mutations; lux lung; uncommon egfr; new data; patients uncommon

Journal Title: Expert Review of Respiratory Medicine
Year Published: 2017

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.